Next Article in Journal
Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on “Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895”
Previous Article in Journal
Pediatric Brain Tumours: Lessons from the Immune Microenvironment
 
 
Comment
Peer-Review Record

The CADTH pCODR Expert Review Committee Process Explained. Comment on Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895

Curr. Oncol. 2023, 30(5), 5047-5049; https://doi.org/10.3390/curroncol30050380
by Maureen Trudeau 1,* and Brent Fraser 2,*
Curr. Oncol. 2023, 30(5), 5047-5049; https://doi.org/10.3390/curroncol30050380
Submission received: 28 February 2023 / Accepted: 9 May 2023 / Published: 16 May 2023
(This article belongs to the Section Breast Cancer)
Back to TopTop